An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

Lilly

Status and phase: Completed; Phase 1

Conditions: Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis

Treatments: Drug: Cetuximab

Study type: Interventional

Funder types: Industry

Identifiers

NCT00207116

CA225-065

Details and patient eligibility

About

The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Measurable disease tumor available for biopsies
• Life expectancy of at least 3 months

Exclusion criteria

• Known or documented brain metastases prior to Cetuximab therapy

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

120 participants in 1 patient group

A

Experimental group

Treatment:

Drug: Cetuximab